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Abstract
Introduction:  Donor  sites  of  split-thickness  skin  grafts  (STSGs)  are  painful  and  limit  patient
rehabilitation.  We  conducted  this  study  to  assess  the  efﬁcacy  of  a  non-adherent  polyurethane
dressing  in  reducing  pain  and  its  effect  on  the  epithelialization  rate  of  donor  sites  of  STSGs.
Methods: Fifteen  patients  requiring  an  STSG  were  included.  In  10  patients  the  donor  sites  were
randomly  divided  into  two  halves  and  covered  with  either  a  non-adherent  polyurethane  dress-
ing or  a  standard  non-adherent  gauze.  In  ﬁve  patients  with  bilateral  donor  sites,  one  side  was
covered with  the  non-adherent  polyurethane  dressing  and  the  other  with  non-adherent  gauze.
The pain  was  assessed  with  a  visual  analog  scale  and  epithelialization  was  also  assessed,  calcu-
lating non-epithelialized  areas  with  image  software  by  a  blinded  surgeon.  Epithelialization  of
the wounds  covered  with  the  non-adherent  polyurethane  dressing  was  assessed  at  day  8  and  10
and those  with  non-adherent  gauze  at  day  10.
Results:  Postoperative  pain  signiﬁcantly  decreased  with  the  non-adherent  polyurethane  dress-
ing during  the  length  of  the  study  (6.07  ±  1.46  vs.  1.72  ±  1.6)  and  at  each  time  point  (p  <  0.001).
Epithelialization  was  not  affected  with  the  polyurethane  dressing,  compared  to  the  standard
method.
Conclusions:  Non-adherent  polyurethane  dressing  achieves  a  signiﬁcant  reduction  of  pain  in  the
skin-grafted  donor  sites  without  affecting  epithelialization.
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medical,  Inc.,  Charlotte,  NC)  and  left  on  site  until  the  8th
day  (Fig.  1).  In  the  patients  with  bilateral  donor  sites,  one
side  was  covered  with  Mepilex® and  the  other  with  Adaptic®Decreased  pain  in  split-thickness  skin  graft  donor  sites  
Introduction
Split  thickness  skin  grafts  (STSGs)  are  routinely  used  to
cover  a  variety  of  wounds  caused  by  burns,  trauma  or  tumor
excisions,  etc.  Due  to  their  reliability  and  the  relatively
high  availability  of  donor  sites,  STSGs  represent  one  of  the
ﬁrst  options  in  reconstruction.1--3 However,  harvesting  STSGs
invariably  produces  a  new  open  wound  in  the  donor  site,
which  can  be  painful  and  requires  fast  and  effective  re-
epithelialization.
Typically,  the  donor  site  is  covered  with  non-adherent
ﬁne-meshed  gauze  impregnated  with  different  ointments.4,5
Unfortunately,  this  technique  is  usually  painful  and  is  one  of
its  main  drawbacks.6 In  fact,  pain  related  to  donor  sites  is
the  most  important  patient  complaint  within  the  ﬁrst  ten
days  after  graft  harvest.7 This  is  particularly  important  in
those  cases  where  prompt  rehabilitation  is  required,  e.g.,
severely  burned  patients.
Recent  technological  advances  have  made  the  creation
of  new  dressings  designed  to  cause  less  discomfort  in  donor
site  wounds  possible.8,9 As  newer  options  are  seen  on  an
almost  daily  basis,  the  current  trend  in  donor-site  manage-
ment  is  oriented  to  reduce  pain  as  well  as  promote  rapid
and  effective  re-epithelialization.10,11
Among  the  dressings  that  have  been  used  in  donor  site
wounds  are  hydrocolloids  (Duoderm®)  that  typically  forms
a  scab  over  the  wound  and  an  exudate  with  an  unpleas-
ant  odor  macerating  the  surrounding  skin,  and  Biobrane®,
a  biocomposite  porcine  type  I  collagen  attached  to  a  ﬂexi-
ble  synthetic  membrane  that  has  been  effective  in  reducing
pain.12 One  of  the  main  issues  with  Biobrane® is  that  ﬂuid
accumulates  underneath  if  not  properly  used,  making  the
area  prone  to  infection.12
Mepilex® (Mölnlycke  Health  Care,  US,  LLC,  Norcross,
GA)  is  a  non-adherent  polyurethane  dressing  consisting  of
a  polyurethane  absorbing  sponge,  adaptable  with  Safetac
Technology®.  According  to  the  manufacturers,  this  technol-
ogy  permits  the  dressing  to  adhere  to  the  surrounding  skin,
but  not  to  the  moist  wound  bed,  potentially  reducing  pain,
preventing  maceration  and  minimizing  the  drag  of  epithe-
lial  cells  at  removal.13,14 Furthermore,  it  seals  the  wound  to
prevent  leakage  of  exudate  and  isolates  the  wound  from  the
environment,  minimizing  skin  infections.14
Due  to  these  characteristics,  it  is  potentially  beneﬁcial
for  STSGs.  We  conducted  a  prospective  and  randomized
study  to  assess  the  efﬁcacy  of  Mepilex® in  reducing  pain  of
STSG  donor  sites  and  on  epithelialization  compared  with  our
traditional  management  (non-adherent  dressing).
Patients and methods
We  conducted  a  prospective,  comparative  and  randomized
clinical  trial  between  January  and  August,  2012.  The  Ethics
Committee  of  our  hospital  approved  the  study  protocol.  All
patients  enrolled  in  the  study  signed  an  informed  consent.
Inclusion  criteria  included  patients  requiring  split-thickness
skin  grafts  secondary  to  any  etiology.  The  patients  were
assigned  to  two  groups.  The  ﬁrst  group  included  ten  patients
with  a  donor  site  of  at  least  20  cm  ×  10  cm  on  one  thigh.
The  second  group  included  ﬁve  patients  who  required  bilat-
eral  harvest  of  STSGs  of  at  least  10  cm  ×  10  cm  on  each
F
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nigure  1  Donor  site  assessment:  (a)  control  area  covered  with
on adherent  gauze,  (b)  Mepilex®-covered  area.
high.  Exclusion  criteria  included  pregnant  women,  immuno-
uppressed  patients,  a  known  allergy  to  any  component  of
he  dressings,  dermatological  diseases,  and  anticoagulant  or
orticosteroid  treatment.
onor  site  management
ll  skin  grafts  were  harvested  from  the  proximal-
nterolateral  thigh  by  the  same  surgeon.  The  grafts  were
arvested  with  a  dermatome  to  produce  a homogeneous
hickness  of  0.4  mm.  In  patients  with  a  unilateral  donor
ite,  the  wound  was  divided  into  proximal  and  distal  halves
nd  randomly  assigned  to  be  covered  with  either  a  non-
dherent  dressing  (Adaptic®, Johnson  &  Johnson,  Inc.,  New
runswick,  NJ),  our  standard  method,  or  Mepilex®. The  area
overed  with  non-adherent  gauze  was  managed  in  a  semi-
pen  fashion,  with  no  secondary  dressing.  The  Mepilex®
atch  was  secured  with  an  adhesive  bandage  (Hypaﬁx®,  BSNigure  2  Patient  with  bilateral  donor  site:  one  side  was  cov-
red with  Mepilex  (right)  and  the  contralateral  side  (left)  with
on-adherent  gauze.
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Figure  3  Donor  site  assessment:  (a)  donor  site  area  to  be  assessed.  The  surgeon  assessing  the  epithelialization  rate  was  blinded
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bo group  and  time  point  of  the  area;  (b)  extension  (in  pixels)  of  
ver the  total  donor  site  area.
s  previously  described  (Fig.  2).  This  assignment  was  ran-
omly  made.
ain
ain  of  donor  sites  was  assessed  with  a  visual  analog  scale
VAS)  using  a  scale  from  0  to  10  on  days  3,  5,  7  and  9  after
rafting.ssessment  of  epithelialization
pithelialization  was  assessed  on  the  8th  and  10th  days
n  the  Mepilex®-covered  areas  and  on  the  10th  day  in  the
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uon-healed  area  was  determined  by  diviiding  the  unhealed  area
reas  covered  with  non-adherent  gauze.  To  remove  the
daptic  gauze,  a  thick  layer  of  petrolatum  was  applied
ver  the  area  on  the  9th  day  and  left  overnight.  The  next
orning  the  adaptic  gauze  was  removed  at  the  patient’s
edside.  This  procedure  was  painless  and  no  analgesic  was
equired.
Mepilex® was  removed  on  the  8th  day  at  the  patient’s
edside.  If  the  Mepilex®-covered  area  was  not  fully  healed
y  the  8th  day,  it  was  covered  again,  as  previously  explained
or  the  Mepilex®-covered  areas.  Photographs  were  taken  of
oth  areas  with  a  digital  camera  (Fuji  Finepix  S,  Super  EBC
ujinon  lens:  26×  Optical  zoom  f  =  4.3--111.8,  1:3.1--5.9)
sing  standardized  photo  settings  (30  cm  distance,  f30,  1/30
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Table  1  Wound  etiology  and  patient  characteristics.
Etiology  n
Trauma  9
Burn 4
Tumor  resection  2
Gender
Male 11
Female  4
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and  ISO  100)  under  standard  daylight  ﬂuorescent  lamps  (GE
T8  Standard  linear  ﬂuorescent  lamp  36  W,  2750  lm).
The  photographs  were  assessed  by  a  plastic  surgeon
blinded  to  the  group  and  to  the  time  point  after  grafting.
Epithelialization  percentage  was  calculated  by  analyzing  the
photographs  of  the  donor  sites  using  image  software  (Adobe
Photoshop®).  Brieﬂy,  the  donor  site  area  was  selected  and
the  amount  of  pixels  within  the  selection  was  determined.
Then,  the  unhealed  areas  were  selected  and  the  respec-
tive  size  of  this  selection  was  determined.  The  percentage
of  epithelialization  was  calculated  by  dividing  the  non-
epithelialized  area  by  the  total  donor  site  surface  area
(Fig.  3a  and  b).
Statistical  analysis
Difference  in  scores  of  the  visual  analog  scale  was  assessed
by  ANOVA  on  Ranks.  The  difference  of  epithelialized  areas
was  assessed  with  one-way  ANOVA  (Sigma  Stat  3.5,  Ger-
many).  Signiﬁcance  was  deﬁned  as  p  <  0.05.
Results
Fifteen  patients  requiring  skin  grafting  for  the  management
of  trauma  injuries  were  included  (Fig.  4).  There  were  11  men
and  4  women  with  a  median  age  of  27  years  (range  10--68)
(Table  1).
Postoperative  donor  site  pain  was  consistently  lower  in
the  areas  covered  with  Mepilex® during  the  study.  The  mean
pain  scores  for  the  entire  treatment  period  were  6.07  ±  1.46
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Figure  4  StudyAge, yrs.  median  (range)  27  (10--68)
or  control  and  1.72  ±  1.6  for  Mepilex®. The  analysis  of  each
ime  point  showed  similar  results:  on  day  three,  patients
eported  a  mean  VAS  score  of  3.4  ±  1.3  for  the  Mepilex®
roup  and  7.07  ±  1.16  for  the  control  group;  at  day  ﬁve
.87  ±  1.55  in  the  Mepilex® group  and  6.33  ±  1.4  in  the
ontrol  group;  at  day  seven  0.93  ±  1.03  in  the  Mepilex®
roup  and  5.8  ±  1.21  in  the  control  group,  and  on  day  nine
.67  ±  0.82  in  the  Mepilex® group  and  5.07  ±  1.39  in  the
ontrol  group  (p  <  0.001)  (Fig.  5).  Further  analysis  revealed
imilar  results  in  the  patients  with  unilateral  treatment
both  for  Mepilex® and  Adaptic  on  the  same  thigh)  and  those
reated  bilaterally  (Mepilex® on  one  thigh  and  Adaptic  on  the
ontralateral  one)  (p  <  0.001)  (Fig.  6a  and  b).
Regarding  epithelialization,  there  was  no  signiﬁcant  dif-
erence  between  both  groups  at  day  ten,  (99.55  ±  0.09%  in
he  Mepilex®-covered  areas  vs.  99.91  ±  0.18%  in  the  con-
rol  group;  p  =  0.69).  At  day  eight,  the  areas  covered  with
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Figure  5  General  Pain  Assessment.  Pain  scores  were  consis-
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Figure  7  General  epithelialization  assessment.  Areas  covered
with  Mepilex  were  partially  epithelialized  at  day  8  (95.94%,)
s
(ently  lower  in  the  Mepilex  group  at  all  times  during  the  study.
 p  <  0.001(see  text  for  details).  VAS:  visual  analog  scale.
epilex® were  only  95.94%  epithelialized,  a  ﬁnding  that
as  statistically  different  with  both  groups  on  the  10th  day
p  = 0.008  vs.  control  and  p  =  0.008  vs.  Mepilex® at  day  ten)
Fig.  7).  The  comparison  between  unilateral  and  bilateral
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igure  6  Pain  assessment  by  groups.  The  analysis  of  the
roups  showed  signiﬁcantly  less  pain  in  the  areas  covered  with
epilex® at  all  time  points  (p  <  0.01).  (a)  Bilateral  donor  sites.
b) Unilateral  donor  sites.  VAS:  visual  analog  scale.
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cigniﬁcantly  different  that  control  and  Mepilex  at  day  10
p =  0.008).  At  day  10,  no  signiﬁcant  difference  was  observed.
reatments  showed  practically  identical  results:  Mepilex®-
overed  areas  were  95.74%  epithelialized  at  day  8  in  the
nilateral  group  vs.  99.38%  at  day  10  (p  =  0.003)  and  vs.
9.92%  in  the  control  group  (p  <  0.001)  (Fig.  8a).  In  the  bilat-
ral  group,  the  areas  covered  with  Mepilex® were  95.94%
ealed  at  day  8  vs.  99.55%  at  day  10  (p  =  0.008)  and  vs.
9.90%  in  the  control  group  (p  =  0.008)  (Fig.  8b).
iscussion
he  choice  of  the  dressing  for  the  donor  site  can  have  a
ajor  impact  on  patient  satisfaction  and  recovery.15 Skin-
raft  harvesting  results  in  large  open  surface  areas  that
re  prone  to  pain,  infection  or  other  morbidities.16,17 Donor
ite  management  plays  an  important  and  critical  role  in  the
volution  and  rehabilitation  of  patients  because  early  reha-
ilitation  and  mobilization  is  critical  for  achieving  optimal
utcomes  in  burn  patients.18,19
Pain  impairs  prompt  rehabilitation,  since  pain  related
o  donor  sites  is  the  most  important  complaint  within
he  ﬁrst  ten  days  after  graft  harvesting  in  burn  patients.7
herefore,  by  decreasing  pain,  we  could  potentially  help
he  early  mobilization  of  patients,  especially  in  pediatric
opulations.
All  kinds  of  dressings  are  reported  in  the  literature  for
onor  site  management,  but  they  all  have  different  draw-
acks  and  the  ideal  dressing  has  yet  to  be  described.20,21
n  our  continuous  search  for  available  material  that  best
uits  the  needs  of  our  burn  patients,  we  decided  to  assess
epilex® for  its  potential  advantage  of  pain  reduction
ithout  affecting  the  epithelium.  The  principal  aim  of
ur  study  was  to  assess  the  reduction  of  pain  of  donor
ites.  Since  pain  is  a  subjective  parameter  and  varies  from
ndividual  to  individual,  it  is  very  difﬁcult  to  make  objec-
ive  and  reliable  measurements.22 Therefore,  we  used  the
AS,  which  is  a  widely-used  and  accepted  tool  for  pain
ssessment.15,23
Donor  areas  were  located  in  the  anterolateral  thigh  in  all
ases  to  reduce  variability  of  pain  related  to  the  topographic
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Figure  8  Epithelialization  assessment  by  groups.  The  areas
covered  with  Mepilex  were  signiﬁcantly  less  epithelialized  at
day 8  than  day  10  in  both  groups.  (A)  Bilateral  donor  sites.
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area.  We  decided  to  include  patients  with  unilateral  and
bilateral  donor  sites  to  compare  the  effect  of  the  dressing
in  reducing  pain  because  either  approach  has  its  pros  and
cons.  In  both  cases,  the  patient  serves  as  his  own  control,
which  is  desirable  since  using  different  patients  for  control
and  treatment  groups  makes  elimination  of  the  psychologi-
cal  effect  of  every  individual  on  the  perception  of  pain  very
difﬁcult,  increasing  the  bias  of  the  study.  By  dividing  the
donor  sites  into  halves  (proximal  and  distal)  we  are  assessing
the  same  anatomic  area,  decreasing  variability  for  a  differ-
ent  topographic  area.  Even  though  there  is  a  reasonable
possibility  for  poor  discrimination  of  pain  between  adja-
cent  zones,  the  scores  were  signiﬁcantly  different  in  both
areas,  conﬁrming  that  the  patient  is  capable  of  discriminat-
ing  the  pain  in  two  adjacent  areas.  The  bilateral  treatment
allowed  removal  of  the  theoretical  difﬁculty  of  effectively
discriminating  pain  in  two  adjacent  areas,  but  it  includes
the  bias  of  two  topographic  areas.  Nevertheless,  since  pain
was  effectively  reduced  with  Mepilex® in  both  cases,  we  can
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tate  its  superiority  over  the  standard  management  in  pain
eduction.
We  usually  remove  the  non-adherent  gauze  of  donor  sites
t  day  10  because  we  have  found  that  epithelialization  is
omplete  by  that  time,  and  previous  attempts  to  remove
he  gauze  earlier  led  almost  invariably  to  unhealed  wounds.
herefore,  we  decided  to  remove  the  dressings  on  that  day
nd  chose  it  as  the  ﬁnal  time  point  for  comparison.
Since  epithelialization  was  practically  completed  in  both
roups  by  day  10  and  this  was  not  statistically  different
p  =  0.29),  we  can  conclude  that  Mepilex® does  not  impair
pithelialization  of  donor  sites.  We  decided  to  remove
epilex® before  the  10th  day  because  we  wanted  to  see  if  it
ould  improve  epithelialization.  It  was  arbitrarily  decided
o  set  day  8  to  assess  epithelialization  in  the  Mepilex® group,
ecause  if  it  actually  did  improve  epithelialization,  this
ould  be  clinically  relevant.  Since  epithelialization  was  sta-
istically  and  clinically-relevant  incomplete  by  day  8,  we
o  not  advise  removal  on  that  day.  A  new  study  would  be
eeded  to  assess  if  Mepilex® can  induce  full  epithelialization
y  day  9,  but  we  believe  that  this  is  unlikely  and  clinically
rrelevant.  An  exception  for  this  would  be  in  severely  burned
atients  who  typically  require  several  graft  takes  and  one
ay  saved  with  each  harvest  would  be  advantageous.
Even  though  the  sample  size  is  relatively  small  (15
atients),  statistical  signiﬁcance  and  power  was  achieved
p  <  0.001,  power  1.00).  Therefore,  we  do  not  believe
hat  increasing  the  sample  size  would  inﬂuence  outcome.
nother  limitation  of  this  study  is  the  fact  that  the  patient
as  not  blinded  to  the  treatment  and  it  is  difﬁcult  to  elimi-
ate  the  placebo  effect.  It  was  not  possible  to  get  dressing
aterial  without  Safetac  Technology.  Perhaps  future  studies
an  compare  other  occlusive  dressing  material  to  determine
f  this  type  of  technology  is  responsible  for  the  observed  pain
eduction  or  the  occlusive  method  per  se.
However,  we  found  that  Mepilex® was  an  easy-to-use
ressing,  painless  at  removal,  and  maintained  its  position
uring  the  whole  treatment  period,  which  is  not  always
ossible  with  other  dressing  materials;  e.g.,  hydrocolloids.
nother  advantage  was  that  in  this  type  of  moderately
xudating  wound,  Mepilex® efﬁciently  absorbed  exudates
ithout  the  need  of  secondary  dressings.  It  was  not  nec-
ssary  to  change  the  patch  due  to  ﬂuid  saturation  at  any
ime.  The  fact  that  there  was  no  impairment  in  the  rate  of
pithelialization  in  the  covered  donor  site  encourages  its  use
n  cases  where  the  donor  area  is  required  to  be  in  contact
ith  the  bed;  e.g.,  posterior  thigh  or  patients  in  a  prone
osition.  It  is  well  known  that  this  practice  may  complicate
hese  areas  with  conventional  management.  There  were  no
eports  of  adverse  effects  with  the  use  of  Mepilex® in  any
atient  and  they  preferred  the  use  of  Mepilex® dressing
nstead  of  standard  management  in  all  cases.
Therefore,  we  can  conclude  that  the  use  of  Mepilex®
ranslates  into  a  signiﬁcant  and  relevant  reduction  of  pain
n  donor  sites  without  affecting  epithelialization.
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anuscript  similar  to  this  study  that  might  be  regarded  as
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